| Abstrakt: |
Patient‐derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three‐dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns of the parental tumors. To ensure that only tumor tissue is used for organoid development, cytologic validation is necessary before initiating the process of organoid generation. Here, we explore the technology of tumor organoids and discuss the fundamental application of cytology as a simple and cost‐effective approach toward organoid development. We also underscore the potential application of organoid development in drug efficacy studies for lung cancer and head and neck tumors. Additionally, we stress the importance of using fine‐needle aspiration to generate tumoroids. The review discusses the use of patient‐derived organoid models in cancer research, emphasizing their potential in diagnosis and personalized medicine. Cytological validation is highlighted as a crucial step in ensuring the identity of tumor tissue for organoid generation. The paper also explores the application of organoids in drug efficacy studies for lung cancer and head and neck tumors, as well as the importance of fine‐needle aspiration in generating tumoroids. [ABSTRACT FROM AUTHOR] |
Plný text